ArticleOncogene2026
Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with over 83% of patients presenting metastases to vital organs such as the liver, lungs, and peritoneum. Although glycosylation has been established as a critical factor in PDAC development, little is known about the molecular underpinnings of organ-specific metastasis. In this study, we investigated the role of glycosyltransferases (GTs) in mediating PDAC metastatic organotropism. Through an unbiased transcriptomic screen, we identified distinct GT expression patterns in liver- and lung-tropic PDAC cells. Notably, GCNT3 and B3GNT3 were selectively upregulated in liver and lung-tropic cells, respectively. These mutually exclusive expression patterns were validated in human metastatic PDAC specimens, where GCNT3 was enriched in liver metastatic lesions and B3GNT3 in lung metastases. Proteomic profiling revealed that differential expression of these GTs is associated with epithelial-mesenchymal transition and glycoproteome remodeling in metastatic cells. Functional studies using in vitro assays, ex vivo organotypic cultures, and in vivo metastasis models demonstrated that loss of GCNT3 or B3GNT3 impairs the proliferation and survival of PDAC cells in their respective metastatic organ environments. Together, these findings uncover a glycosylation-based mechanism that facilitates organ-specific survival of metastatic PDAC cells and highlight glycosyltransferases as potential therapeutic targets for disrupting metastatic adaptation.
Identifiers
42533113What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.